Gottlieb: FDA’s EUA For Remdesivir Is ‘Broad,’ Gives Doctors Flexibility

FDA on Friday (May 1) issued Emergency Use Authorization for Gilead’s remdesivir to treat lab-confirmed COVID-19 in hospitalized adults and children. Though the agency says the EUA is indicated for severe disease, former FDA chief Scott Gottlieb sees it as a broad authorization that also seems to apply to moderate COVID-19 patients. He also noted the agency’s recommended dosing regimen of five days effectively allows Gilead to extend its supply of the drug. “A big win for patients and the...